Skip to content
2000
image of Pharmacodynamic Interactions: Mechanisms, Clinical Trial Insights, and Patent Perspectives

Abstract

Pharmacodynamic interactions are relevant in improving drug efficiency without a significant increase in the effects due to toxicity and, in most, are associated with polypharmacy. Mechanisms that govern pharmacodynamic interactions are additive, synergistic, and also antagonistic. Additive drug interactions refer to effects similar to a summation of effects resulting from administering a pair of drugs or a series, while synergistic describes a heightened response much above what one might have aspired to in light of expectations about additivity. However, the antagonistic effect may weaken therapeutic activity at times. Mechanistic pathways like receptor binding, enzyme inhibition, and modulation of signaling pathways were also studied to bring out their relevance in clinical applications. The manuscript is conscious of the role of patents and clinical trials in understanding pharmacodynamic interactions. Patents provide insight into new drug combinations and mechanisms, and the same interaction gets validated through the outcome of clinical trials. Examples that prove clinical relevance have emerged through the synergy in the usage of the drugs for oncology, cisplatin and etoposide, or the additive effect of aspirin and clopidogrel in preventing thrombotic events. The transformative approaches applied in developing drugs include network pharmacology, epigenetics, and receptor crosstalk. In this review, the pharmacodynamic interactions, by integrating mechanistic insights with clinical data, patents, and case studies, explicitly underpin pharmacodynamic interactions as a factor that enhances drug safety, efficacy, and therapeutic precision.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266384427250923131856
2025-10-10
2026-02-28

  • From This Site

    /content/journals/ctmc/10.2174/0115680266384427250923131856
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Farooq A. Drotleff B. Kroemer N. Han M.L. Li J. Decousser J.W. Schrey D. Buyck J. Grégoire N. Nordmann P. Wicha S.G. Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime-avibactam with tigecycline in ESBL- and carbapenemase producing Escherichia coli and Klebsiella pneumoniae. Int. J. Antimicrob. Agents 2025 65 4 107457 10.1016/j.ijantimicag.2025.107457 39894062
    [Google Scholar]
  2. Calzetta L. Page C. Matera M.G. Cazzola M. Rogliani P. Drug-drug interactions and synergy: From pharmacological models to clinical application. Pharmacol. Rev. 2024 76 6 1159 1220 10.1124/pharmrev.124.000951 39009470
    [Google Scholar]
  3. Papotti B. Marchi C. Adorni M.P. Potì F. Drug-drug interactions in polypharmacy patients: The impact of renal impairment. Curr. Res. Pharm. Drug Disc. 2021 2 100020 10.1016/j.crphar.2021.100020 34909655
    [Google Scholar]
  4. Sommer J. Seeling A. Rupprecht H. Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs Aging 2020 37 5 359 372 10.1007/s40266‑020‑00747‑0 32056163
    [Google Scholar]
  5. Tallarida R.J. Raffa R.B. McGonigle P. Tallarida R.J. Raffa R.B. McGonigle P. Pharmacodynamics: The interaction of drugs with receptors. In: Principles in General Pharmacology Springer, New York, NY, 1988 151 197
    [Google Scholar]
  6. Hill S. Pharmacodynamics. Anaesth. Sci. 2006 26 39
    [Google Scholar]
  7. Koch G. Schropp J. Jusko W.J. Assessment of non-linear combination effect terms for drug–drug interactions. J. Pharmacokinet. Pharmacodyn. 2016 43 5 461 479 10.1007/s10928‑016‑9490‑0 27638639
    [Google Scholar]
  8. Martín-López L.M. Rojo J.E. Gibert K. Martín J.C. Sperry L. Duñó L. Bulbena A. Vallejo J. The strategy of combining antidepressants in the treatment of major depression: Clinical experience in spanish outpatients. Depress. Res. Treat. 2011 2011 1 1 8 10.1155/2011/140194 21738865
    [Google Scholar]
  9. Gurbel P.A. Tantry U.S. Clopidogrel resistance? Thromb. Res. 2007 120 3 311 321 10.1016/j.thromres.2006.08.012 17109936
    [Google Scholar]
  10. Solomon V.R. Tallapragada V.J. Chebib M. Johnston G.A.R. Hanrahan J.R. GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators. Eur. J. Med. Chem. 2019 171 434 461 10.1016/j.ejmech.2019.03.043 30928713
    [Google Scholar]
  11. Yang L. Lyu H. Yiming A. Xu X. Ma C. Tu S. Chen B. Liu M. Wu C. Integrated metabolism, network pharmacology, and pharmacokinetics to explore the exposure differences of the pharmacodynamic material basis in vivo caused by different extraction methods for Saussurea involucrata. J. Ethnopharmacol. 2022 298 115648 10.1016/j.jep.2022.115648 35987408
    [Google Scholar]
  12. de Lera A.R. Ganesan A. Epigenetic polypharmacology: From combination therapy to multitargeted drugs. Clin. Epigenetics 2016 8 1 105 10.1186/s13148‑016‑0271‑9 27752293
    [Google Scholar]
  13. Noda K. Nishiwaki Y. Kawahara M. Negoro S. Sugiura T. Yokoyama A. Fukuoka M. Mori K. Watanabe K. Tamura T. Yamamoto S. Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002 346 2 85 91 10.1056/NEJMoa003034 11784874
    [Google Scholar]
  14. Jamerson K. Weber M.A. Bakris G.L. Dahlöf B. Pitt B. Shi V. Hester A. Gupte J. Gatlin M. Velazquez E.J. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008 359 23 2417 2428 10.1056/NEJMoa0806182 19052124
    [Google Scholar]
  15. Baldo B.A. Toxicities of opioid analgesics: Respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Arch. Toxicol. 2021 95 8 2627 2642 10.1007/s00204‑021‑03068‑2 33974096
    [Google Scholar]
  16. Chaachouay N. Synergy, additive effects, and antagonism of drugs with plant bioactive compounds. Drugs and Drug Candidates 2025 4 1 4 10.3390/ddc4010004
    [Google Scholar]
  17. Bandaru S. Alvala M. Nayarisseri A. Sharda S. Goud H. Mundluru H.P. Singh S.K. Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor. PLoS One 2017 12 10 0186666 10.1371/journal.pone.0186666 29053759
    [Google Scholar]
  18. Criscione L. Bradley W.A. Bühlmayer P. Whitebread S. Glazer R. Lloyd P. Mueller P. de Gasparo M. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin‐II antagonist. Cardiovasc. Drug Rev. 1995 13 3 230 250 10.1111/j.1527‑3466.1995.tb00305.x
    [Google Scholar]
  19. Gudin J. Fudin J. A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther. 2020 9 1 41 54 10.1007/s40122‑019‑00143‑6 31994020
    [Google Scholar]
  20. Infantino R. Mattia C. Locarini P. Pastore A.L. Maione S. Luongo L. Buprenorphine: Far beyond the “ceiling”. Biomolecules 2021 11 6 816 10.3390/biom11060816 34072706
    [Google Scholar]
  21. Patadiya N. Panchal N. Vaghela V. A review on enzyme inhibitors. International Research Journal Of Pharmacy 2021 12 6 60 66 10.7897/2230‑8407.1206145
    [Google Scholar]
  22. Istvan E.S. Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001 292 5519 1160 1164 10.1126/science.1059344 11349148
    [Google Scholar]
  23. Meek I.L. Van de Laar M.A. E Vonkeman H. Non-steroidal anti-inflammatory drugs: An overview of cardiovascular risks. Pharmaceuticals 2010 3 7 2146 2162 10.3390/ph3072146 27713346
    [Google Scholar]
  24. Behar M. Barken D. Werner S.L. Hoffmann A. The dynamics of signaling as a pharmacological target. Cell 2013 155 2 448 461 10.1016/j.cell.2013.09.018 24120141
    [Google Scholar]
  25. K Bhanumathy K. Balagopal A. Vizeacoumar F.S. Vizeacoumar F.J. Freywald A. Giambra V. Protein tyrosine kinases: Their roles and their targeting in leukemia. Cancers 2021 13 2 184 10.3390/cancers13020184 33430292
    [Google Scholar]
  26. An X. Tiwari A.K. Sun Y. Ding P.R. Ashby C.R. Jr Chen Z.S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk. Res. 2010 34 10 1255 1268 10.1016/j.leukres.2010.04.016 20537386
    [Google Scholar]
  27. Pugsley MK Curtis MJ Hayes ES Biophysics and molecular biology of cardiac ion channels for the safety pharmacologist. Handb Exp Pharmacol 2015 229 149 203 10.1007/978‑3‑662‑46943‑9_7
    [Google Scholar]
  28. Rahm C. Fundamental principles of pharmacology. J. Clin. Med. Eng. 2024 2 1 37
    [Google Scholar]
  29. Boczek T. Mackiewicz J. Sobolczyk M. Wawrzyniak J. Lisek M. Ferenc B. Guo F. Zylinska L. The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. Focus on GPCRs activated by neurotransmitters and chemokines. Cells 2021 10 5 1228 10.3390/cells10051228 34067760
    [Google Scholar]
  30. Pharmacodynamic interactions of propofol and dexmedetomidine on intravenous anesthesia. NCT Patent 02777619 2016
  31. To investigate PK and PD of CJ-12420, clarithromycin, and amoxicillin after multiple dose administration. NCT Patent 03011996 2017
  32. To evaluate whether naproxen and darexaban (YM150) interact in their effects. NCT Patent 01409603 2011
  33. To evaluate whether aspirin, the combination of aspirin and clopidogrel, and darexaban (YM150) interact in their effects. NCT Patent 01409616 2011
  34. Modeling and application of triple drug response surface models. NCT Patent 03813875 2019
  35. To evaluate whether aspirin and darexaban (YM150) interact in their effects. NCT Patent 01424332 2011
  36. The effect of genetic polymorphism on interactions of clopidogrel and cilostazol in healthy volunteers. NCT Patent 01482117 2011
  37. Pharmacokinetic and pharmacodynamic interactions between ezetimibe and efavirenz. NCT Patent 00810303 2009
  38. Effects of laquinimod on standard oral contraceptive in young healthy women. NCT Patent 02085863 2014
  39. Drug-drug interactions between DWP14012 and aspirin in healthy subjects. NCT Patent 05304845 2022
  40. Prescription medication interactions. NCT Patent 04315181 2020
  41. Drug-drug interactions between DWP14012 and DWC202202 in healthy subjects. NCT Patent 05574374 2023
  42. Rivaroxaban Hypericum trial. NCT Patent 03796377 2019
  43. Effect of metformin and daclatasvir on metformin PK/PD. NCT Patent 03686722 2019
  44. Pharmacodynamic interaction of REMI and DMED (PIRAD). NCT Patent 03143972 2018
  45. Effects of posaconazole and voriconazole on the PK/PD of sublingual buprenorphine. NCT Patent 01367808 2011
  46. Pharmacodynamic drug interaction between cilostazol and statins (SMCCPT-100). NCT Patent 01870466 2013
  47. Pharmacodynamic drug interaction between warfarin and amoxicillin-clavulanic acid (INWARA). NCT Patent 00603317 2008
  48. Drug interaction study of isavuconazole and warfarin in healthy male subjects. NCT Patent 01657825 2012
  49. PK/PD drug-drug interaction of evogliptin and glimepiride. NCT Patent 02954822 2016
  50. Opioid and cannabinoid interactions. NCT Patent 03705559 2018
  51. Influence of pantoprazole on the bioavailability of MMF and EC-MPS. NCT Patent 01801280 2013
  52. Interaction between ABT-335, rosuvastatin, and warfarin. NCT Patent 00487136 2007
  53. PK/PD drug-drug interaction of evogliptin and pioglitazone. NCT Patent 02753803 2016
  54. Buprenorphine/raltegravir pharmacokinetic interaction study. NCT Patent 00858962 2009
  55. Food interaction study with AZD1722 tablet in healthy subjects. NCT Patent 02226783 2014
  56. PK/PD interaction study of digoxin and hawthorn. NCT Patent 00006330 2001
  57. PK/PD interactions between oral roflumilast and inhaled formoterol. NCT Patent 00940329 2010
  58. PK/PD interaction between BIA 3-202 and levodopa/benserazide. NCT Patent 02778594 2016
  59. PK/PD interaction between BIA 3-202 and levodopa/carbidopa. NCT Patent 02774564 2016
  60. Interactions between intravenous cocaine and acetazolamide or quinine. NCT Patent 01851473 2015
  61. Interaction between fluvoxamine and sildenafil. NCT Patent 00175981 2005
  62. PK/PD interaction of remimazolam and remifentanil. NCT Patent 04670471 2020
  63. PK/PD interactions of tasimelteon and ethanol. NCT Patent 01578057 2012
  64. Alcohol interaction study. NCT Patent 01181908 2010
  65. Pharmacodynamic interaction between tropisetron and paracetamol. NCT Patent 00487110 2007
  66. PK/PD interaction of lofexidine and buprenorphine. NCT Patent 01820442 2013
  67. PK/PD interaction of pyrimethamine and metformin IR. NCT Patent 01973933 2013
  68. Influence of morphine on PK/PD of ticagrelor in AMI patients (IMPRESSION). NCT Patent 02217878 2014
  69. PK/PD interaction of tipranavir and ritonavir with loperamide. NCT Patent 02251119 2014
  70. PK/PD drug-drug interaction and safety/tolerability between RLD2202 and RLD2203. NCT Patent 05481307 2022
  71. Antacid interaction study. NCT Patent 01982201 2013
  72. RDEA3170 and febuxostat drug interaction study. NCT Patent 01883167 2013
  73. Martin J Emmanuelle C Krzysztof C Methods and compositions for rna-directed target dna modification and for RNA-directed modulation of transcription. JP Patent 2023123755A 2023
  74. Wilhelm-Ogunbi-Kate K Stewart BG Wiltshire TH Dosing regimen for sedation with CNS 7056 (remimazolam). KR Patent 102059399B1 2019
  75. Tracy A Glauser RJ Wenstrup AA Drug selection and medication optimization and personalization. JP Patent 5567107B2 2014
  76. Hong L Hong L Yasmina NA PCSK9 antagonist. JP Patent 6060212B2 2017
  77. Krieg AM Krieg AM Combination tumor immunotherapy. JP Patent 6885867B2 2021
  78. Glidden PF Pilgrim AJ Hanson SR Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor. US Patent 9750698B2 2017
  79. Weber E Janssen J Fontaine TMJ Apparatus and method for assessing levels of consciousness, pain, and nociception during arousal, sedation, and general anesthesia. CN Patent 107847172B 2021
  80. Babul N. Multimodal abuse-resistant and extended-release opioid formulations. US Patent 9125833B2 2015
  81. Sysko RA Sysko SK Minor JM Systems and methods for disease control and management. US Patent 20240290461A1 2024
  82. Davidson P Almog S Kindler S Methods, devices, and systems for pulmonary delivery of active agents. RU Patent 2728689C2 2020
  83. Gautier L Anse N Ligier A Multispecific NKp46 binding protein. JP Patent 6822849B2 2021
  84. Adelman B Biedenkapp J Chyung Y Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema. AU Patent 2020244370B2 2024
  85. Kohnen A Schmidt M Koko W Novel RNA-programmable endonuclease system and uses thereof. JP Patent 7550648B2 2024
  86. Coleman SH Suture sleeve patch and methods of delivery within an existing arthroscopic workflow. AU Patent 2016344019B2 2021
  87. Shellenberger V Podust V Wang C-W Xten conjugate compositions and methods of making same. KR Patent 102057356B1 2019
  88. Wilson BR Grant M Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. US Patent 20230414500A1 2023
  89. Cohen A Schmidt M Coco W RNA-programmable endonuclease systems and their use in genome editing and other applications. US Patent 11578323B2 2023
  90. Ingber DE Hajipouran Benam K Villenave R Ingber Low shear microfluidic devices and methods of use and manufacturing thereof. US Patent 11940441B2 2024
  91. Herman A Iyope E Bulova E Anti-CTLA-4 antibodies and uses thereof. KR Patent 102710122B1 2024
  92. Corman AJ Romberg N Fontana DJ Combination of anti-LAG-3 and anti-PD-1 antibodies for treating tumors. JP Patent 7480248B2 2024
  93. Rosario Wyant M Prediction of outcome of treatment with anti-α4β7 integrin antibodies. JP Patent 7530314B2 2024
  94. Chan C Hackett CG Sriram V Compositions and methods for disabling bone marrow cells that express TREM1. JP Patent 7267280B2 2023
  95. Scherli RT Lansbury PT Good AC Substituted pyrazolo[1,5-a] pyrimidines and their use in treating medical disorders. JP Patent 7519221B2 2024
  96. Griffith L Trumper D Edington C Modular organ micro physiological system with integrated pumping, leveling, and sensing. US Patent 11732229B2 2023
  97. Chen H Annis DA Chang Y Peptidomimetic macrocycles and uses thereof. US Patent 20230106577A1 2023
  98. Amin N Graham N Pirozzi G IL-4R antagonist for use in a method for treating or preventing asthma. EP Patent 3703818B1 2023
  99. Wilson BR Grant M Method for improving the pharmaceutical properties of microparticles comprising diketopiperazine and an active agent. US Patent 20230414500A1 2023
  100. Li YS Rui L Xu J Cytokine-based bioactivatable drugs and methods of uses thereof. US Patent 20240141005A1 2024
  101. Elliott MW Fisher TS Sharp LL Combination of anti-4-1BB antibody and ADCC derived antibody for the treatment of cancer. JP Patent 6313825B2 2018
  102. Trialists’ Collaboration BPLT Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000 356 9246 1955 1964
    [Google Scholar]
  103. Vandraas K.F. Spigset O. Mahic M. Slørdal L. Non-steroidal anti-inflammatory drugs: Use and co-treatment with potentially interacting medications in the elderly. Eur. J. Clin. Pharmacol. 2010 66 8 823 829 10.1007/s00228‑010‑0825‑2 20405110
    [Google Scholar]
  104. Rossi S. Hallett M. Rossini P.M. Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin. Neurophysiol. 2009 120 12 2008 2039 10.1016/j.clinph.2009.08.016 19833552
    [Google Scholar]
  105. Saadat-Gilani K. Zarbock A. Meersch M. Perioperative renoprotection: Clinical implications. Anesth. Analg. 2020 131 6 1667 1678 10.1213/ANE.0000000000004995 33186156
    [Google Scholar]
  106. Grymonprez M. Capiau A. Steurbaut S. Boussery K. Mehuys E. Somers A. Pharmacodynamic drug-drug interactions and bleeding outcomes in patients with atrial fibrillation using non-vitamin K antagonist Oral anticoagulants: A Nationwide cohort study. Cardiovasc. Drugs Ther. 2023 ••• 1 11 37930588
    [Google Scholar]
  107. Bhatara V.S. Magnus R.D. Paul K.L. Preskorn S.H. Serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann. Pharmacother. 1998 32 4 432 436 10.1345/aph.17041 9562139
    [Google Scholar]
  108. Patel R. Patel P. Patel N. Gangwani J. Patel D. Case report on the interaction between furosemide and digoxin that caused digoxin toxicity. J. Drug Deliv. Ther. 2022 12 5-S 9 12 10.22270/jddt.v12i5‑S.5717
    [Google Scholar]
  109. Ernst M.E. Buys L.M. Reevaluating the Safety of Concurrent Warfarin and Ibuprofen Therapy: A Case Report. J. Pharm. Technol. 1997 13 6 244 247 10.1177/875512259701300610
    [Google Scholar]
  110. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract-influence of physiological, pathophysiological and pharmaceutical factors. Front. Pharmacol. 2020 11 524 10.3389/fphar.2020.00524 32425781
    [Google Scholar]
  111. Wang W. Ye Z. Gao H. Ouyang D. Computational pharmaceutics - A new paradigm of drug delivery. J. Control. Release 2021 338 119 136 10.1016/j.jconrel.2021.08.030 34418520
    [Google Scholar]
  112. Vinarov Z. Abrahamsson B. Artursson P. Batchelor H. Berben P. Bernkop-Schnürch A. Butler J. Ceulemans J. Davies N. Dupont D. Flaten G.E. Fotaki N. Griffin B.T. Jannin V. Keemink J. Kesisoglou F. Koziolek M. Kuentz M. Mackie A. Meléndez-Martínez A.J. McAllister M. Müllertz A. O’Driscoll C.M. Parrott N. Paszkowska J. Pavek P. Porter C.J.H. Reppas C. Stillhart C. Sugano K. Toader E. Valentová K. Vertzoni M. De Wildt S.N. Wilson C.G. Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv. Drug Deliv. Rev. 2021 171 289 331 10.1016/j.addr.2021.02.001 33610694
    [Google Scholar]
  113. Watanabe H. Nagano N. Tsuji Y. Noto N. Ayusawa M. Morioka I. Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Eur. J. Clin. Pharmacol. 2024 80 2 203 221 10.1007/s00228‑023‑03598‑x 38078929
    [Google Scholar]
  114. Zhao D. Huang P. Yu L. He Y. Pharmacokinetics–pharmacodynamics modeling for evaluating drug–drug interactions in polypharmacy: Development and challenges. Clin. Pharmacokinet. 2024 63 7 919 944 10.1007/s40262‑024‑01391‑2 38888813
    [Google Scholar]
  115. Jagtiani E. Yeolekar M. Naik S. Patravale V. In vitro blood brain barrier models: An overview. J. Control. Release 2022 343 13 30 10.1016/j.jconrel.2022.01.011 35026351
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266384427250923131856
Loading
Pharmacodynamic Interactions: Mechanisms, Clinical Trial Insights, and Patent Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/0115680266384427250923131856
/content/journals/ctmc/10.2174/0115680266384427250923131856
/content/journals/ctmc/10.2174/0115680266384427250923131856
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: additive ; Pharmacodynamic interactions ; synergistic ; antagonistic ; patents ; clinical trials

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test